CA2284192A1 - Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus - Google Patents

Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus Download PDF

Info

Publication number
CA2284192A1
CA2284192A1 CA002284192A CA2284192A CA2284192A1 CA 2284192 A1 CA2284192 A1 CA 2284192A1 CA 002284192 A CA002284192 A CA 002284192A CA 2284192 A CA2284192 A CA 2284192A CA 2284192 A1 CA2284192 A1 CA 2284192A1
Authority
CA
Canada
Prior art keywords
tetrahydro
benzoic acid
tetramethyl
naphthyloxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002284192A
Other languages
English (en)
French (fr)
Inventor
Andrea Fanjul
Magnus Pfahl
Waldemar Lernhardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2284192A1 publication Critical patent/CA2284192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Vapour Deposition (AREA)
CA002284192A 1997-03-24 1998-03-24 Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus Abandoned CA2284192A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3560497P 1997-03-24 1997-03-24
US60/035,604 1997-03-24
PCT/US1998/005591 WO1998042340A1 (en) 1997-03-24 1998-03-24 Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
CA2284192A1 true CA2284192A1 (en) 1998-10-01

Family

ID=21883695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284192A Abandoned CA2284192A1 (en) 1997-03-24 1998-03-24 Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Country Status (11)

Country Link
EP (1) EP1019049A1 (pt)
JP (1) JP2001521551A (pt)
KR (1) KR20010005678A (pt)
CN (1) CN1256630A (pt)
AU (1) AU6576398A (pt)
BR (1) BR9808054A (pt)
CA (1) CA2284192A1 (pt)
IL (1) IL132032A0 (pt)
NO (1) NO994612L (pt)
NZ (1) NZ337927A (pt)
WO (1) WO1998042340A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
PT1131070E (pt) * 1998-11-12 2008-11-19 Smithkline Beecham Plc Composição farmacêutica para libertação modificada de um sensibilizador à insulina e de outro agente antidiabético
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
WO2005070413A1 (ja) * 2004-01-23 2005-08-04 Japan Science And Technology Agency レチノイン酸を含有する糖尿病治療薬
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
CN106211757B (zh) 2014-01-17 2022-06-07 康奈尔大学 使用维甲酸受体激动剂治疗代谢综合征相关病况的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504847A (ja) * 1989-03-08 1992-08-27 ザ　ユニバーシティ　オヴ　バージニア　パテント　ファウンデーション インスリン抵抗性糖尿病のための食事用補添物
FR2695317B1 (fr) * 1992-09-07 1995-03-10 Monal Lab Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
US5560908A (en) * 1993-01-22 1996-10-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5444086A (en) * 1994-03-31 1995-08-22 American Home Products Corporation Naphthalenylmethyl thiophenones as antihyperglycemic agents

Also Published As

Publication number Publication date
NO994612D0 (no) 1999-09-22
KR20010005678A (ko) 2001-01-15
BR9808054A (pt) 2000-11-07
NZ337927A (en) 2000-11-24
IL132032A0 (en) 2001-03-19
WO1998042340A1 (en) 1998-10-01
AU6576398A (en) 1998-10-20
NO994612L (no) 1999-11-24
JP2001521551A (ja) 2001-11-06
EP1019049A1 (en) 2000-07-19
CN1256630A (zh) 2000-06-14

Similar Documents

Publication Publication Date Title
US6028052A (en) Treating NIDDM with RXR agonists
EP0859608B1 (en) Treating niddm with rxr agonists
Spencer et al. Troglitazone
DE60124861T2 (de) Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CN104739841B (zh) 合成三萜类化合物及用以治病之方法
CA2684016A1 (en) Methods and compounds for inhibiting amyloid deposits
Zhang et al. Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats.
KR20030059287A (ko) Ｇａｂａ 작용제 및 알도스 리덕타제 억제제의 혼합물
WO2000035867A1 (fr) Nouveaux ligands d'un recepteur nucleaire
AU2001270402B2 (en) A new use for deferiprone
CA2284192A1 (en) Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
WO1998042340A9 (en) Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
US20070037882A1 (en) Remedy for cerebral neurodegenerative diseases using ppar agonist
WO2007007757A1 (ja) PPARγアゴニストを含有する医薬組成物
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
KR20010012556A (ko) 다낭포성 난소 증후군 및 임신성 당뇨병의 치료에 있어서5-(4-(2-(ｎ-메틸-ｎ-(2-피리딜)아미노)-에톡시)벤질)2,4-티아졸리딘디온의 용도
MXPA99008765A (en) Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (niddm) using specific retinoid compounds
Boyle What are the effects of peroxisome proliferator‐activated receptor agonists on adiponectin, tumor necrosis factor‐alpha, and other cytokines in insulin resistance?
JP2005514399A (ja) ＰＰＡＲγアクチベーターの投薬法
Wang Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas
RU2191007C2 (ru) Способ лечения иhcд агонистами rxr
CA2232288C (en) Treating niddm with rxr agonists
MXPA98002104A (en) Compositions using a rxr agonist only or in combination with a ppar agonist, to treat diabetes mellitus not dependent on insul
Kashihara et al. Clinical and Biochemical Effects of Calcium‐Hopantenate on Neuroleptics‐Induced Tardive Dyskinesia

Legal Events

Date Code Title Description
FZDE Discontinued